The Fourth Editorial Board Meeting of Hepatoma Research Journal Was Held in Wuhan, Hubei Province, China
The Fourth Editorial Board Meeting of the journal Hepatoma Research (HR) was successfully held in Wuhan City, China on December 8, 2019, sponsored by 2019 Chinese Academic Conference on Tumor Biomarker (CCTB) and the 13th Youth Scientists Forum on Tumor Biomarker.
Seventeen Editorial Board Members participated in the meeting. During the meeting, they looked back on the overall development of HR in 2019 and formulated its strategic plan for 2020.
Some Editorial Board members in the meeting
The Editorial Board Meeting schedule included academic presentations in the morning and journal development reports on the afternoon of December 8, 2019.
Key reports include:
Topic: Risk Prediction, Early Diagnosis and Prognostic Markers of HCC
Speaker: Prof. Guang-Wen Cao, Vice President, Cancer epidemiology Committee of China Anti-Cancer Association.
Topic: AFP Regulates Transcription Factor ZHX2 and Liver Cancer
Speaker: Prof. Chun-Hong Ma, Shandong University, Qingdao, Shandong, China.
Topic: CHI3L1 in Sensitive and Dynamic Monitoring of Changes in Liver Fibrosis
Speaker: Prof. Biao-Yang Lin, Zhejiang University, Hangzhou, Zhejiang, China.
Topic: Challenges in Clinical Application of Serum Markers in Early Diagnosis of HCC
Speaker: Prof. Hui-Guo Ding, Beijing You'an Hospital affiliated to Capital Medical University, Beijing, China.
Topic: Study on the Molecular Mechanism of Aspirin Regulating Collagen Synthase P4HA2 to Inhibit the Growth of Liver Cancer
Speaker: Prof. Li-Hong Ye, Nankai University, Tianjin, China.
Speakers on Editorial Board Meeting of "Liver Cancer Special Section of CCTB"
In the afternoon, Professor Guang-Wen Cao, the Editor-in-Chief, reported on journal development and discussed the hot topics in liver cancer with editorial board members.
Prof. Cao and other Editorial Board members in discussion on the journal development
HR has been committed to producing high-quality, standardized scientific publications since its foundation in April 2015. Although going through some difficult times at the beginning, HR has never held back. Where there is a will, there is a way. HR has developed from nothing to something, and from small to big over the past four years. In 2019, HR became a membership of International Committee on Publication Ethics (COPE). At present, HR is gaining support and recognition from many distinguished experts in the liver cancer field. HR owes recognition to those who propped up the journal, and believes more and more scholars will support the journal in the near future. Moreover, HR will consistently strive to bring more valuable academic reports to this field and present satisfactory results to readers.